IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment ...
Edwards Lifesciences’ SAPIEN M3 mitral valve replacement system has become the first transcatheter therapy utilizing a transseptal approach to snag FDA approval in the U.S. for the treatment of mitral ...
One-year outcomes in the ENCIRCLE trial’s main cohort (299 patients unsuitable for other treatment options) achieved low rates for death and low heart failure hospitalization for patients treated with ...
Widening the Transcatheter Heart Valve Therapy (THVT) product suite, Edwards Lifesciences Corporation EW recently announced the receipt of CE Mark for the SAPIEN 3 Ultra system for transcatheter ...
Edwards Lifesciences Corp. (Irvine, CA) has announced both the FDA approval and the U.S. launch of its next-generation Sapien XT transcatheter aortic heart valve for the treatment of high-risk and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results